381 related articles for article (PubMed ID: 31715145)
21. Expression of p53-related protein p63 in the gastrointestinal tract and in esophageal metaplastic and neoplastic disorders.
Glickman JN; Yang A; Shahsafaei A; McKeon F; Odze RD
Hum Pathol; 2001 Nov; 32(11):1157-65. PubMed ID: 11727253
[TBL] [Abstract][Full Text] [Related]
22. Hypomethylation of noncoding DNA regions and overexpression of the long noncoding RNA, AFAP1-AS1, in Barrett's esophagus and esophageal adenocarcinoma.
Wu W; Bhagat TD; Yang X; Song JH; Cheng Y; Agarwal R; Abraham JM; Ibrahim S; Bartenstein M; Hussain Z; Suzuki M; Yu Y; Chen W; Eng C; Greally J; Verma A; Meltzer SJ
Gastroenterology; 2013 May; 144(5):956-966.e4. PubMed ID: 23333711
[TBL] [Abstract][Full Text] [Related]
23. Differential MicroRNA Signatures in the Pathogenesis of Barrett's Esophagus.
Craig MP; Rajakaruna S; Paliy O; Sajjad M; Madhavan S; Reddy N; Zhang J; Bottomley M; Agrawal S; Kadakia MP
Clin Transl Gastroenterol; 2020 Jan; 11(1):e00125. PubMed ID: 31934893
[TBL] [Abstract][Full Text] [Related]
24. Identification of the putative intestinal stem cell marker doublecortin and CaM kinase-like-1 in Barrett's esophagus and esophageal adenocarcinoma.
Vega KJ; May R; Sureban SM; Lightfoot SA; Qu D; Reed A; Weygant N; Ramanujam R; Souza R; Madhoun M; Whorton J; Anant S; Meltzer SJ; Houchen CW
J Gastroenterol Hepatol; 2012 Apr; 27(4):773-80. PubMed ID: 21916995
[TBL] [Abstract][Full Text] [Related]
25. Loss of glutathione peroxidase 7 promotes TNF-α-induced NF-κB activation in Barrett's carcinogenesis.
Peng DF; Hu TL; Soutto M; Belkhiri A; El-Rifai W
Carcinogenesis; 2014 Jul; 35(7):1620-8. PubMed ID: 24692067
[TBL] [Abstract][Full Text] [Related]
26. Reprimo methylation is a potential biomarker of Barrett's-Associated esophageal neoplastic progression.
Hamilton JP; Sato F; Jin Z; Greenwald BD; Ito T; Mori Y; Paun BC; Kan T; Cheng Y; Wang S; Yang J; Abraham JM; Meltzer SJ
Clin Cancer Res; 2006 Nov; 12(22):6637-42. PubMed ID: 17121882
[TBL] [Abstract][Full Text] [Related]
27. Malignant degeneration of Barrett's esophagus: the role of the Ki-67 proliferation fraction, expression of E-cadherin and p53.
Feith M; Stein HJ; Mueller J; Siewert JR
Dis Esophagus; 2004; 17(4):322-7. PubMed ID: 15569371
[TBL] [Abstract][Full Text] [Related]
28. Independent Blinded Validation of a Tissue Systems Pathology Test to Predict Progression in Patients With Barrett's Esophagus.
Davison JM; Goldblum J; Grewal US; McGrath K; Fasanella K; Deitrick C; DeWard AD; Bossart EA; Hayward SL; Zhang Y; Critchley-Thorne RJ; Thota PN
Am J Gastroenterol; 2020 Jun; 115(6):843-852. PubMed ID: 32079863
[TBL] [Abstract][Full Text] [Related]
29. Population-based study reveals new risk-stratification biomarker panel for Barrett's esophagus.
Bird-Lieberman EL; Dunn JM; Coleman HG; Lao-Sirieix P; Oukrif D; Moore CE; Varghese S; Johnston BT; Arthur K; McManus DT; Novelli MR; O'Donovan M; Cardwell CR; Lovat LB; Murray LJ; Fitzgerald RC
Gastroenterology; 2012 Oct; 143(4):927-35.e3. PubMed ID: 22771507
[TBL] [Abstract][Full Text] [Related]
30. Adenocarcinoma arising in Barrett's oesophagus: evidence for the participation of p53 dysfunction in the dysplasia/carcinoma sequence.
Hardwick RH; Shepherd NA; Moorghen M; Newcomb PV; Alderson D
Gut; 1994 Jun; 35(6):764-8. PubMed ID: 8020801
[TBL] [Abstract][Full Text] [Related]
31. Subtypes of Barrett's oesophagus and oesophageal adenocarcinoma based on genome-wide methylation analysis.
Yu M; Maden SK; Stachler M; Kaz AM; Ayers J; Guo Y; Carter KT; Willbanks A; Heinzerling TJ; O'Leary RM; Xu X; Bass A; Chandar AK; Chak A; Elliott R; Willis JE; Markowitz SD; Grady WM
Gut; 2019 Mar; 68(3):389-399. PubMed ID: 29884612
[TBL] [Abstract][Full Text] [Related]
32. Chromosomal abnormalities and novel disease-related regions in progression from Barrett's esophagus to esophageal adenocarcinoma.
Akagi T; Ito T; Kato M; Jin Z; Cheng Y; Kan T; Yamamoto G; Olaru A; Kawamata N; Boult J; Soukiasian HJ; Miller CW; Ogawa S; Meltzer SJ; Koeffler HP
Int J Cancer; 2009 Nov; 125(10):2349-59. PubMed ID: 19670330
[TBL] [Abstract][Full Text] [Related]
33. Statins inhibit proliferation and induce apoptosis in Barrett's esophageal adenocarcinoma cells.
Ogunwobi OO; Beales IL
Am J Gastroenterol; 2008 Apr; 103(4):825-37. PubMed ID: 18371146
[TBL] [Abstract][Full Text] [Related]
34. Increased CDX2 and decreased PITX1 homeobox gene expression in Barrett's esophagus and Barrett's-associated adenocarcinoma.
Lord RV; Brabender J; Wickramasinghe K; DeMeester SR; Holscher A; Schneider PM; Danenberg PV; DeMeester TR
Surgery; 2005 Nov; 138(5):924-31. PubMed ID: 16291394
[TBL] [Abstract][Full Text] [Related]
35. Dynamic changes in microRNA expression profiles reflect progression of Barrett's esophagus to esophageal adenocarcinoma.
Slaby O; Srovnal J; Radova L; Gregar J; Juracek J; Luzna P; Svoboda M; Hajduch M; Ehrmann J
Carcinogenesis; 2015 May; 36(5):521-7. PubMed ID: 25784377
[TBL] [Abstract][Full Text] [Related]
36. Genetic profiles of Barrett's esophagus and esophageal adenocarcinoma in Japanese patients.
Tokunaga M; Okimoto K; Akizue N; Ishikawa K; Hirotsu Y; Amemiya K; Ota M; Matsusaka K; Nishimura M; Matsushita K; Ishikawa T; Nagashima A; Shiratori W; Kaneko T; Oura H; Kanayama K; Ohta Y; Taida T; Saito K; Matsumura T; Chiba T; Mochizuki H; Arai M; Kato J; Ikeda JI; Omata M; Kato N
Sci Rep; 2021 Sep; 11(1):17671. PubMed ID: 34480065
[TBL] [Abstract][Full Text] [Related]
37. Expression profiles of cancer stem cell markers: CD133, CD44, Musashi-1 and EpCAM in the cardiac mucosa-Barrett's esophagus-early esophageal adenocarcinoma-advanced esophageal adenocarcinoma sequence.
Mokrowiecka A; Veits L; Falkeis C; Musial J; Kordek R; Lochowski M; Kozak J; Wierzchniewska-Lawska A; Vieth M; Malecka-Panas E
Pathol Res Pract; 2017 Mar; 213(3):205-209. PubMed ID: 28216140
[TBL] [Abstract][Full Text] [Related]
38. [p53 Protein expression from mild dysplasia to adenocarcinoma in a patient with Barrett's esophagus: an immunohistochemical study].
Bustamante M; Bernet L
Rev Esp Enferm Dig; 2006 Aug; 98(8):631-3. PubMed ID: 17049004
[No Abstract] [Full Text] [Related]
39. Identification of Subtypes of Barrett's Esophagus and Esophageal Adenocarcinoma Based on DNA Methylation Profiles and Integration of Transcriptome and Genome Data.
Jammula S; Katz-Summercorn AC; Li X; Linossi C; Smyth E; Killcoyne S; Biasci D; Subash VV; Abbas S; Blasko A; Devonshire G; Grantham A; Wronowski F; O'Donovan M; Grehan N; Eldridge MD; Tavaré S; ; Fitzgerald RC
Gastroenterology; 2020 May; 158(6):1682-1697.e1. PubMed ID: 32032585
[TBL] [Abstract][Full Text] [Related]
40. p53-mutant clones and field effects in Barrett's esophagus.
Prevo LJ; Sanchez CA; Galipeau PC; Reid BJ
Cancer Res; 1999 Oct; 59(19):4784-7. PubMed ID: 10519384
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
